Brainstorm Cell Therapeutics | BCLI - Cash And Equivalent


Brainstorm Cell Therapeutics reported $5K in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Biogen USD 3.01B 854.3M Dec/2025
Brainstorm Cell Therapeutics USD 5K 819K Sep/2025
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 7.46M 985K Sep/2025
CSL USD 2.16B 633M Jun/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 419.66M 357.8M Sep/2025
Mesoblast USD 62.56M 14.58M Jun/2024